["As per the given context from the \"Assessing User Fees Under the Generic Drug User Fee Amendments of 2022,\" DMF holders do not need to wait for a new ANDA (Abbreviated New Drug Application) applicant to request a letter of authorization before the DMF is assessed to be available for reference. The completion of a Comprehensive Assessment (CA) and payment of the DMF fee are the key factors in determining the availability of the DMF for reference by generic drug submission applicants.\n\nOnce the DMF fee is paid and the DMF has passed the completeness assessment, including confirmation of its activity status, it is considered available for reference. The DMF number is then made publicly available on the FDA's website to indicate its availability for reference by generic drug submission applicants.\n\nSimilarly, if a generic drug submission contains all necessary Active Pharmaceutical Ingredient (API) information and does not reference a DMF, it is required to pay an (a)(3)(F) fee, and no CA will be conducted. However, the DMF availability for reference is not dependent on a specific request from a new ANDA applicant or the issuance of a letter of authorization.\n\nOverall, the availability of the DMF for reference by generic drug submission applicants is primarily determined by the completion of the DMF fee payment and the successful assessment of its completeness, as outlined in the regulatory guidelines under the Generic Drug User Fee Amendments.", "As per the provided contexts, the Direct Final Rule Procedures Guidance for FDA and Industry primarily focuses on the rulemaking process and does not specifically address the safety criteria for consumer antiseptic wash active ingredients. Therefore, for clarification on the safety criteria for consumer antiseptic wash active ingredients, it would be advisable to refer to the specific regulations and guidance documents related to antiseptic wash products. These may include the Final Rule on Consumer Antiseptic Rubs, the Nonprescription Sunscreen Drug Products \u2013 Safety and Effectiveness Data, and the Enforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the COVID-19 Public Health Emergency, among others.\n\nHowever, based on the provided contexts regarding control of components, production and process controls, calculation of yield, equipment identification, packaging and labeling operations, reserve samples, and records retention as outlined in the \"Preparation of Investigational New Drug Products (Human and Animal) Guidance for Industry\", it is evident that these requirements are specific to investigational new drug products and may not directly apply to consumer antiseptic wash active ingredients. Therefore, it is important to seek specific guidance or regulations related to consumer antiseptic wash products to determine the safety criteria for these active ingredients.", "In accordance with the Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice (CGMP) Regulations, the records maintained by the Quality Assurance Unit (QAU) should be retained in compliance with the relevant regulatory guidelines. It's important to note that the specifics of record retention may vary based on the individual company's policies and applicable regulations. Additionally, the guidelines regarding record retention may be influenced by the type and duration of the study conducted.\n\nSpecifically, for nonclinical safety studies in the pharmaceutical industry, the assessment of reversibility and the retention of related records should align with the international M3(R2) guidelines for Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals as well as Good Laboratory Practice (GLP) regulations.\n\nAccording to the M3(R2) guidelines, the evaluation of reversibility of toxicity should be provided in cases where there is severe toxicity in a nonclinical study with potential adverse clinical impact. The guidelines state that assessment of reversibility is necessary when there is severe toxicity at clinically relevant exposures or when the toxicity is only detectable at an advanced stage of the pathophysiology in humans. In such cases, the evaluation can be based on a study of reversibility or on a scientific assessment, and it is important to provide evidence to support the potential for reversibility.\n\nWhile the guidelines do not specifically outline the location of retention for QAU records, it is crucial for companies to adhere to applicable regulatory requirements and industry best practices when determining the appropriate retention of these records. This includes ensuring that QAU records are retained in a manner that facilitates their availability for inspection by regulatory authorities, if required.\n\nIt is pertinent to emphasize that the retention of QAU records should align with the company's quality policy and the principles outlined in the Quality Systems Approach to Pharmaceutical CGMP Regulations, management responsibility, and in compliance with relevant guidelines such as ICH Q10 Pharmaceutical Quality System.\n\nTo ensure compliance with the applicable regulations and to support potential reversibility assessments, it is essential for companies to establish and follow documented procedures for the retention of QAU records, including those related to nonclinical safety studies. Additionally, companies should regularly review and update their record retention practices to ensure ongoing compliance with regulatory requirements.", "In the given context, the guidance most relevant to the question about adding additional testing on the same subject to the dataset falls under \"Assay Migration Studies for In Vitro Diagnostic Devices Guidance for Industry and FDA Staff.\" The context provides detailed information on the migration studies paradigm, study designs, and performance criteria for sponsors seeking to migrate a previously approved, licensed, or cleared assay to another system.\n\nThe guidance outlines the option for additional studies to be performed for the new system, specifically in the context of precision studies, performance at low analyte levels, and carry-over or cross-contamination studies. Furthermore, it emphasizes the need for appropriate study designs and validation prior to migration, and it offers non-binding recommendations for specific study designs and performance evaluations.\n\nThus, within the context of assay migration studies, adding additional testing on the same subject to the dataset may be appropriate, especially when focusing on precision studies, performance at low analyte levels, and carry-over or cross-contamination studies to ensure the appropriate validation and performance of the migrated assay on the new system.\n\nIf you have specific questions or need additional details, you may consider reaching out directly to the FDA staff responsible for implementing this guidance through the contact information provided in the context.", "In accordance with the given context from \"CVM GFI #156 Comparability Protocols - Chemistry, Manufacturing, and Controls Information for New Animal Drugs\" the rationale for differences in equipment, critical or quality related steps and controls should consider the following aspects as outlined in the guidance:\n\n- The guidance from CVM GFI #156 serves to delineate the manufacturing activities between engaged parties, suggesting how they can use quality agreements to establish the delineation and the responsibilities in order to ensure compliance with CGMP requirements.\n\n- It also highlights that the current good manufacturing practice (CGMP) requirements are applicable not only for manufacturing but also encompass processing, packing, holding, labeling operations, testing, and quality unit operations. The guidance provides a framework for the roles and manufacturing activities of the parties involved in contract manufacturing arrangements.\n\n- When an owner uses a contract facility, the owner's quality unit is legally responsible for approving or rejecting drug products manufactured by the contract facility, including for final release. Thus, the quality control and oversight mechanism is defined for the responsible party, ensuring that they evaluate the manufacturing activities for compliance with CGMP requirements.\n\n- The guidance specifies that each party engaged in the manufacture of a drug is responsible for ensuring compliance with CGMP for the manufacturing activities it performs. This includes managing the risk and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products.\n\nTherefore, the focus of the guidance is to establish a clear understanding and delineation of manufacturing responsibilities between parties engaged in contract manufacturing, and to ensure that compliance with CGMP requirements is maintained throughout the manufacturing process.", "I'm sorry, but I couldn't find the specific reference to the estimated time the FDA expects firms to compile and provide communications of follow-up information regarding previously communicated information to payors about their unapproved products or unapproved uses of approved/cleared products in the provided documents, including \"Display Devices for Diagnostic Radiology,\" \"Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices,\" \"Content of Premarket Submissions for Device Software Functions,\" \"Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation,\" \"Manufacturers Sharing Patient-Specific Information from Medical Devices with Patients Upon Request,\" and \"Medical Device Reporting for Manufacturers Guidance for Industry and Food and Drug Administration Staff.\" If you need further assistance, please let me know and I'll be glad to help you further.", "Referring to the Product Identifier Requirements Under the Drug Supply Chain Security Act (DSCSA) and the Linear Barcode Requirement under 21 CFR 201.25, the guidance specifies that a manufacturer or repackager can voluntarily put the 2D data matrix barcode on all levels of packaging, including the immediate container. However, the context emphasizes that the linear barcode requirements established under 21 CFR 201.25 are separate and still in effect. Therefore, both the 2D data matrix barcode, as required under the DSCSA, and the linear barcode, as required under 21 CFR 201.25, may be necessary for compliance with the respective regulations. It is important to adhere to the specific requirements under each regulation to ensure compliance.", "The regulations for the protection of human subjects outlined in 21 CFR Parts 50 and 56 are specific to FDA-regulated clinical investigations and seek to ensure informed consent for participants involved in research. These regulations are tailored to the unique mission and authority of the FDA and are designed to promote consistency and understanding of human subject protections within the context of FDA-regulated research. The regulations do not currently include an exception from informed consent for minimal-risk clinical investigations.\n\nOn the other hand, the HHS regulations in 45 CFR Part 46, subpart A, often referred to as the Common Rule, govern the protection of human subjects involved in research conducted or supported by HHS and 15 other federal departments and agencies. The Common Rule permits Institutional Review Boards (IRBs) to waive the requirements to obtain informed consent or to allow changes to, or omission of, some or all elements of informed consent under specific conditions. The Common Rule also allows for the waiver of informed consent for minimal risk research if specific criteria are met.\n\nWhile the FDA has harmonized its regulations to the extent appropriate and permissible with the Common Rule, the FDA's regulations do not currently include an exception from informed consent for minimal-risk clinical investigations.\n\nIn summary, the FDA regulations for protection of human subjects, 21 CFR Parts 50 and 56, differ from the HHS regulations in 45 CFR Part 46 subpart A in the specific provisions related to the waiver or alteration of informed consent for minimal-risk research. While the Common Rule allows for such waivers under specific conditions, the FDA regulations currently do not include such an exception.\n\nThis information provides an understanding of the differences in the regulatory approaches to human subject protections between the FDA regulations and the HHS regulations in the context of informed consent for minimal-risk research.", "After reviewing the provided contexts related to FDA's Policy on Declaring Small Amounts of Nutrients and Dietary Ingredients, it is important to note that the definition of added sugars encompasses sugars from concentrated fruit and vegetable juices that are in excess of what would be expected from the same volume of 100 percent fruit or vegetable juice of the same type.\n\nIn this context, fruit and vegetable products that are considered to have added sugars include those where concentrated fruit or vegetable juices are used as ingredients and contribute sugars that exceed what would be expected from the same volume of 100 percent fruit or vegetable juice of the same type. For example, powdered fruit and vegetable juices made from 100 percent juices and sold to consumers with instructions to reconstitute with water to single strength (100 percent) are considered to have added sugars when the sugars in the powder are in excess of what would be expected from the same volume of 100 percent fruit or vegetable juice of the same type.\n\nAdditionally, in the case of dried fruits, if additional sugar is added, the sugar added to the dried fruit must be declared on the label as added sugars. However, dried fruits without added sugars are not considered to contain added sugars because they are essentially dehydrated whole fruits and still retain the nutrients and other components of a whole fruit.\n\nOverall, this guidance provides details about the declaration of added sugars and the types of fruit and vegetable products that are considered to have added sugars based on the concentrations of sugars from concentrated fruit and vegetable juices that exceed what would be expected from the same volume of 100 percent fruit or vegetable juice of the same type.", "In the context of the E14 Clinical Evaluation of QT:QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs, if the thorough QT study results in a negative finding at the therapeutic dose but the supratherapeutic dose shows a mean effect between 10 and 20 ms, the appropriate course of action depends on the anticipated exposure levels in the patient population and the potential proarrhythmic risk.\n\n1. If there is reasonable assurance that the higher dose represents drug exposures unlikely to be seen in the patient population, only routine ECG monitoring is recommended in late-phase trials, providing reassurance for safety.\n\n2. If supratherapeutic exposure is anticipated at the clinical dose only in a well-characterized subgroup, intensive monitoring as described in Example 2 above could be carried out in this subset of the phase 3 population. This depends on whether the higher exposure is likely to be seen in the general patient population.\n\n3. However, if the supratherapeutic exposure is likely to be seen in the general patient population, intensive ECG monitoring in the phase 3 population is expected, similar to the approach outlined in Example 2.\n\nIt's important to assess the potential for substantial QT prolongation at concentrations expected in clinical studies and to adjust the intensity of monitoring and assessment in late-stage trials accordingly. This might involve considering factors such as the magnitude of QTc prolongation, PK properties of the drug, patient characteristics, and the presence of adverse effects that can increase proarrhythmic risk.\n\nIntensive ECG monitoring in clinical trials should focus on protecting patients who might have large worrisome QT intervals and identifying the frequency of marked QT increases. The timing of ECG collection should be based on the known properties of the drug, with baseline, steady-state, and periodic ECGs recommended during the trial.\n\nOverall, the appropriate approach to ECG monitoring and assessment in late-stage trials will depend on the specific circumstances of the drug and the potential impact of its QT prolongation effects on the patient population. If there are further questions, it's advisable to discuss these approaches with the relevant regulatory agency prior to initiation of the phase 3 program.\n", "Nonmutagenic, carcinogenic impurities should be controlled according to ICH M7(R2) if they are present in the drug substance at levels relevant to safety. ICH M7(R2) provides guidance on the assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. While ICH M7(R2) specifically addresses mutagenicity, the principles outlined in this guideline can also be used to inform the control and management of nonmutagenic, carcinogenic impurities. The applicant should use risk-based reasoning to determine the appropriate steps to include in the hazard assessment for potential nonmutagenic, carcinogenic impurities and should provide a discussion of the risk assessment when identifying the point in the synthesis where these impurities are included in the assessment. Additionally, the suitability of the proposed control strategy can be supported with information about any nonmutagenic, carcinogenic impurities formed or purged in the manufacturing steps between the proposed starting material and the drug substance or that are controlled in the specification of the proposed starting material.", "Based on the information provided, the specific aspects of SUPAC-MR that are relevant to your question about scale-up and postapproval changes among three ANDA submission batches for components and composition are outlined in the following contexts:\n\n1. Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation (SUPAC-MR: Modified Release Solid Oral Dosage Forms)\n2. GUIDANCE DOCUMENT: SUPAC-IR Questions and Answers about SUPAC-IR Guidance\n\nFrom the mentioned contexts, it seems that the level one and level two variations and changes are permitted among the three ANDA submission batches for components and composition, subject to specific criteria and documentation requirements detailed in the SUPAC-MR and SUPAC-IR guidance documents. These documents detail specific levels of changes, corresponding test documentation, and the filing requirements for each level of change.\n\nIt is important to note that the decision on whether a specific change falls within level one or level two would depend on the specific characteristics and requirements outlined in the relevant regulatory guidelines. Therefore, it is essential to carefully evaluate the specific circumstances and ensure compliance with the relevant guidelines for any proposed changes.\n\nFor more specific guidance on this matter, I recommend consulting the full text of the SUPAC-MR and SUPAC-IR guidance, as well as seeking input from regulatory experts or relevant authorities to ensure accurate and compliant interpretation of the guidelines.", "The FDA does not exclusively recommend a graded dosing scheme as the only safe and effective way to take KI (potassium iodide) during radiation emergencies. The FDA has made recommendations on the lowest effective dose, acknowledging that higher doses, up to 130 mg, would also be effective and extremely safe, particularly among school-age children. The FDA's guidance on dosing KI in radiation emergencies adheres to principles of minimum effective dose and recommends graded dosing according to age. This is based on differences in overall benefit versus risk in different population groups. The benefits from thyroid blockade with KI predominate in younger individuals, where the risks of thyroid cancer from radioiodine exposure are the greatest. The risks of KI take on more prominence in older adults, in whom the risks of thyroid cancer are very small. However, the FDA emphasizes that if local emergency planners conclude that implementing a graded dosing scheme is logistically impractical, administrations of up to 130 mg of KI instead of the lower recommended doses for certain age groups are considered acceptable. It is important to note that these recommendations are provided in the context of the FDA's guidance for the use of KI in radiation emergencies, and the specific circumstances of a given emergency situation should be considered when determining the appropriate dosing approach.", "With reference to the Format and Content of the Nonclinical Pharmacology:Toxicology Section of an Application* Guidance for Industry, the protection of whole slide image files, including when transmitted to external users, does not directly align with the content provided in the given contexts. Therefore, I recommend referring directly to the specific guidelines related to the protection, handling, and transmission of digital image files, as well as the applicable regulations governing data protection in the pharmaceutical industry. If you have further specific questions or need clarification on a different topic, please feel free to ask.", "Based on the provided context, the ICH Q7 document should be read in its entirety regardless of the nature of the manufacturing activities being conducted. This is essential for understanding the linkages between different sections and successfully implementing appropriate Good Manufacturing Practices (GMPs) at all stages of the Active Pharmaceutical Ingredients (API) supply chain, including distribution. It is also important to note that the ICH Q7 should be applied in combination with the principles laid down for development and manufacturing in ICH Q11, Quality Risk Management (ICH Q9), and Pharmaceutical Quality Systems (ICH Q10).\n\nFurthermore, it is mentioned that the ICH Q7 guidance should be applied to the manufacturing of mixtures when they are classified as APIs in regions or countries where they are used in drug products. Additionally, the ICH Q7 also describes principles of GMPs to be applied in the manufacture of APIs for use in clinical trials and for APIs manufactured by cell culture/fermentation.\n\nIn summary, the ICH Q7 document should be thoroughly reviewed and implemented in conjunction with related ICH guidelines to ensure GMP compliance in the manufacturing of APIs and throughout the supply chain.", "Based on the provided context from the \"Informed Consent Guidance for IRBs, Clinical Investigators, and Sponsors\" published by the U.S. Department of Health and Human Services and the Food and Drug Administration, there are no explicit mentions of new requirements for informed consent documents in the given context. The focus of the provided context is primarily on the general requirements for informed consent, including guidance on the consent process, informed consent forms, delegation of consent discussion, financial relationships and interests, and review of the consent process by IRBs.\n\nHowever, it is important to clarify that the document's content and the guidance it provides may not directly address new requirements for informed consent documents. It is advisable to consult the latest updates and specific regulations to ensure compliance with any recent changes or amendments to the informed consent requirements.\n\nIf you have specific questions regarding new requirements for informed consent documents, it is recommended to reach out to the Office of Clinical Policy at the U.S. Food and Drug Administration for further clarification and guidance.", "According to the \"Interpretation of the 'Deemed to be a License' Provision of the Biologics Price Competition and Innovation Act of 2009 Guidance for Industry,\" the key differences in the content of prescribing information for biological products regulated under the PHS Act are related to the demonstration of biosimilarity. The guidance specifies that a stepwise approach is recommended to develop the evidence needed to demonstrate biosimilarity, and sponsors need to demonstrate that the proposed product is biosimilar to a single U.S.-licensed reference product that has been previously licensed by the FDA.\n\nThe guidance also emphasizes that a sponsor must provide adequate information to demonstrate biosimilarity based on data directly comparing the proposed product with the U.S.-licensed reference product as a scientific matter. This includes analytical studies and at least one clinical PK study and, if appropriate, at least one PD study, intended to support a demonstration of biosimilarity unless scientifically justified otherwise. Additionally, the guidance suggests that the sponsor may seek to use data derived from animal or clinical studies comparing the proposed product with a non-U.S.-licensed comparator product, but they must provide adequate data or information to scientifically justify the relevance of these comparative data to an assessment of biosimilarity and establish an acceptable bridge to the U.S.-licensed reference product.\n\nMoreover, the complexities of protein products and related scientific considerations are highlighted, emphasizing the need for thorough assessment of potential differences in protein structure and modifications, as well as the impact of different manufacturing processes. The guidance recommends early discussions with the FDA about product development plans and approaches to providing adequate scientific justifications, as early engagement with the Agency is expected to facilitate biosimilar development.\n\nOverall, the key differences in the content of prescribing information for biological products regulated under the PHS Act revolve around the detailed evidence required to demonstrate biosimilarity to a U.S.-licensed reference product and the scientific considerations related to the complexities of protein products and manufacturing processes.", "In the context of the question regarding the calculation of added sugars from diluted or concentrated fruit or vegetable juice ingredients, the regulatory guidelines most relevant to this question are the \"Guidance for Industry- Nutrition and Supplement Facts Labels Questions and Answers Related to the Compliance Date, Added Sugars, and Declaration of Quantitative Amounts of Vitamins and Minerals.\" This guidance provides specific information and considerations for calculating the amount of added sugars in various scenarios involving the use of fruit or vegetable juice ingredients and their concentration or dilution during the production process.\n\nThe provided context includes specific instructions and considerations for calculating added sugars, such as determining the sugar concentration, assessing the impact of water loss during processing, and understanding the regulatory requirements for declaring added sugars based on different formulations and processing methods. It also discusses key principles related to the evaluation of sugars from concentrated fruit or vegetable juices, the exclusion of some sugars from the definition of added sugars, and specific formatting requirements for nutrition and supplement facts labels.\n\nAdditionally, the \"Guidance for Industry- Ingredients Declared as Evaporated Cane Juice\" is also relevant to understanding the characteristics and labeling requirements for certain sugar cane products, offering insights into the common or usual names for different types of sugar products and how they should be accurately labeled on food products.\n\nThese guidelines offer comprehensive information and recommendations to assist in accurately determining and declaring the amount of added sugars from fruit or vegetable juice ingredients, taking into account various processing methods and product formulations.", "Based on the contexts provided, the \"Identity\" tests in accordance with the Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients (APIs) are highly specific for the drug product and are based on unique aspects of its molecular structure and other specific properties. These identity tests can be qualitative in nature and may include physicochemical, biological, and/or immunochemical methods. The tests are intended to establish the unique identity of the drug product and can involve more than one test, if necessary, to accurately establish its identity.\n\nIn the context of API manufacturing, these identity tests play a crucial role in ensuring that APIs meet the necessary requirements for quality and purity, as they are designed to confirm the specific molecular characteristics and properties of the drug product. Therefore, the \"Identity\" tests under Q7 GMP guidance are essential in verifying the unique identity of the API and are typically based on specific aspects of its molecular structure and properties.", "The specific regulatory guidance document relevant to the question would be \"Guidance for Industry - Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products\" issued by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) in November 1995. This guidance clarifies the requirements for data and data presentation in 21 CFR 312.22 and 312.23 related to the initial entry into human studies in the United States of an investigational drug, including well-characterized, therapeutic, biotechnology-derived products. It aims to help expedite the entry of new drugs into clinical testing by increasing transparency and reducing the ambiguity and inconsistencies in the submission process, while providing FDA with the necessary data to assess the safety of the proposed Phase 1 study. This guidance clarifies the process for submitting Chemistry, Manufacturing, and Control (CMC) information and Pharmacology and Toxicology (P/T) information and recommends specific manufacturing data appropriate for Phase 1 investigation.\n\nIn summary, FDA is issuing this guidance document to provide a more efficient and flexible model for the evaluation of multiple versions of an investigational product that would otherwise be evaluated in separate clinical studies. It aims to increase transparency and reduce ambiguity in data submission, and provides clarity on how to structure and organize INDs and submit changes or new information as the study progresses. This guidance aims to minimize the submission of the same information to multiple INDs by facilitating cross-referencing to shared information in the INDs, thus streamlining the submission process and reducing redundancy.", "The information provided in the \"Sponsor - Investigator - IRB Interrelationship Guidance for Institutional Review Boards and Clinical Investigators\" does not directly address the question related to IRB membership categories. Therefore, the guidelines most relevant to the question are not provided in the contexts given.\n\nHowever, based on general knowledge, the diverse membership requirements of an IRB are typically outlined in 21 CFR 56.107(a) and FDA regulations. These requirements include considerations of race, gender, cultural backgrounds, and sensitivity to community attitudes. The regulations also specify that IRB membership should have a diversity of representative capacities and disciplines.\n\nTo specifically address the question, one member may satisfy more than one membership category. For example, a member could be unaffiliated with the institution and have a primary concern in a non-scientific area, therefore satisfying two membership requirements. The FDA regulations acknowledge that individuals with training in both scientific and non-scientific disciplines may hold multiple roles within the IRB.\n\nAdditionally, when members frequently have conflicts and must absent themselves from deliberation and abstain from voting, their contributions to the group review process may be diminished and could hinder the review procedure, as specified in the guidance provided in the Sponsor - Investigator - IRB Interrelationship document.", "Based on the provided context from the FDA's guidance on Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency, the types of inspections deemed \"mission-critical\" are as follows:\n\n1. For-cause inspections: These include inspections conducted in response to specific drug quality problems or facility issues that come to the FDA's attention, including follow-up inspections.\n\n2. Preapproval and pre-license inspections: These are conducted to assess a marketing application or verify conformance with current good manufacturing practice (CGMP) requirements and to confirm that data submitted in the application are accurate and complete.\n\nThe FDA's assessment of whether an inspection is mission-critical considers factors related to the public health benefit, including breakthrough therapy designation, orphan-drug designation, regenerative medicine advanced therapy designation, inclusion in the Drug Shortage or CBER-Regulated Products Shortage list, use for critical care or as a medical countermeasure, and use to diagnose, treat, mitigate, cure, or prevent a serious disease or medical condition (e.g., COVID-19) for which there is no other appropriate and available treatment.\n\nAdditionally, post-approval, surveillance, and for-cause inspections may be deemed mission-critical, taking into account concerns about the safety of investigators, employees at a site or facility, and clinical trial participants and other patients at investigator sites.\n\nIt's important to note that the determination of mission-critical inspections applies to both domestic and foreign inspections, and for foreign inspections, may also be influenced by considerations related to travel restrictions and alternative tools for evaluation.\n\nIn summary, mission-critical inspections include those related to products vital for public health, those related to product shortages, and those necessary to ensure compliance with regulations and maintain the safety and effectiveness of drug products.", "With regard to the question, \"For liquid dosing studies where the test article mixture is made by dilution of the highest dose, which dose should be analyzed?\" in the context of your query, it is important to highlight that the most relevant information can be found in the M3(R2) nonclinical safety studies guideline. This guideline states that the lowest dose would be appropriate since it would confirm the efficacy of the dilution process; however, the GLPs do not prohibit the analysis of any of the other doses.\n\nIn this case, the GLPs, or Good Laboratory Practices, do not mandate a specific dose for analysis. However, the lowest dose is often chosen to confirm the effectiveness of the dilution process, as mentioned in the context provided. This practice aligns with the general principle of ensuring the accuracy and reliability of the dosing process and subsequent analysis. It is important to note that the choice of which dose to analyze should also consider the potential impact on safety and effectiveness assessments in relation to the specific nonclinical study being conducted.\n\nAdditionally, the specific details related to GLP requirements for sample retention and stability evaluations provided within the given contexts do not directly address the question at hand. Therefore, the M3(R2) nonclinical safety studies guideline is the most relevant source for addressing the specific question about dose analysis in liquid dosing studies.\n\nIf there are any additional questions or a need for further clarification on this topic or related regulatory guidelines, please feel free to let me know!", "Based on the insights from the provided regulation contexts, the Small Entity Compliance Guide from the Dietary Supplement Labeling Guide in Chapter III states that for a dietary supplement, the net quantity of contents statement must express the quantity in either weight, measure, numerical count, or a combination of numerical count and weight or measure. When expressing this quantity as a weight or measure, it must be specified in both metric and U.S. Customary System terms. However, it does not explicitly mention that units of measurement specified for use in the \"Nutrition Facts\" panel must be used for the net quantity of contents statement. Therefore, it is advisable to comply with the units of measurement specified for use in the \"Nutrition Facts\" panel, as it would align with the standardized presentation of dietary supplement labeling and assist consumers in understanding the information consistently across different types of nutritional content.", "Based on the information provided, it appears that the context of the question does not directly address the use of primates in nonclinical laboratory studies under the Good Laboratory Practice (GLP) guidelines. The specific context focuses on pharmaceutical current good manufacturing practice regulations, quality management systems, and preclinical safety testing for biotechnology-derived pharmaceuticals.\n\nThe regulations cited in the given contexts do not explicitly address the prohibition of using primates for multiple nonclinical laboratory studies under GLP. However, they emphasize the importance of ensuring the quality and reliability of nonclinical safety studies and the compliance with GLP. They also acknowledge that some studies employing specialized test systems, which are often needed for biopharmaceuticals, may not be able to fully comply with GLP.\n\nTo provide a specific answer to the question, it would be important to consult the appropriate guidelines related to the use of primates in nonclinical laboratory studies and GLP. These guidelines may fall under different regulations or guidelines specifically focused on the use of animals in nonclinical testing, such as those provided by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) or the relevant regulatory authorities.", "The guidance document \"Assay Migration Studies for In Vitro Diagnostic Devices\" does not explicitly address the acceptability of eliminating data that appear to be outliers. However, it does emphasize the need for analytical studies and performance evaluations to be based on the idea that similar studies were conducted previously for the old system. The FDA recommends using fresh clinical specimens for all analytical studies and that specific precision panel compositions be considered, ensuring the inclusion of true negative, low positive, and moderately positive samples in precision panels for qualitative assays. The guidance also discusses the importance of handling missing values and outliers appropriately. It highlights the need for clear identification of outliers, with justifications being medical as well as statistical. The guidance recommends that any procedure for dealing with outliers set out in the protocol or the statistical analysis plan should not favor any treatment group a priori. Furthermore, it suggests that if no procedure for dealing with outliers was foreseen in the trial protocol, at least one analysis eliminating or reducing the outlier effect should be performed and differences between their results discussed.\n\nTherefore, it is crucial to ensure that any elimination of data that appear to be outliers is based on sound scientific justifications and that the medical and statistical context is considered before taking any action. The guidance underscores the importance of proper handling of outliers and their potential impact on study outcomes, emphasizing the need for transparency in discussing any differences resulting from outlier analyses.", "In the context of the given regulatory guidelines related to the Sponsor - Investigator - IRB Interrelationship, the concept of expedited review is not directly addressed. Therefore, I can provide general information on expedited review as it relates to research activities involving human subjects reviewed by an Institutional Review Board (IRB).\n\nIn the context of IRB Continuing Review After Clinical Investigation Approval, expedited review refers to a method of reviewing research activities involving human subjects that pose no more than minimal risk. This expedited review procedure allows for the review of minimal risk research by the IRB chairperson or by designated experienced reviewers from among the members of the IRB. The categories of research activities eligible for expedited review are defined in accordance with the requirements set forth in 45 CFR 46.110 and 21 CFR 56.110.\n\nAdditionally, the context related to the Exception from Informed Consent Requirements for Emergency Research discusses the responsibilities of sponsors, clinical investigators, and IRBs in emergency research studies. It emphasizes the need to provide a detailed investigational plan, including informed consent procedures and an informed consent document, and procedures and information for family member objections. This context outlines the sponsor's responsibilities for meeting various requirements under 21 CFR 50.24, including submitting the protocol to the FDA, obtaining FDA's written authorization, and facilitating community consultation activities.\n\nAs per the given contexts, the focus is primarily on the responsibilities and procedures related to emergency research and the relationship between sponsors, clinical investigators, and IRBs. The guidance does not explicitly delve into the specifics of expedited review. If you require further information or clarification on any other aspects related to the Sponsor - Investigator - IRB Interrelationship or specific guidelines on expedited review, please feel free to ask.", "Based on the provided context on the FDA regulatory guidelines, the question regarding the labeling requirements for raw agricultural commodities, such as fresh fruits and vegetables, falls under the jurisdiction of the \"Guidance for Industry- Food Allergen Labeling Exemption Petitions and Notifications\" and the \"Compilance Policy Guide (CPG) Sec 562.450 Identity of Foods - Use of Terms Such as Fresh, Frozen, Dried, Canned, Etc.\"\n\nIn relation to the question, raw agricultural commodities, such as fresh fruits and vegetables in their natural state, may be exempt from the food allergen labeling requirements of the FD&C Act. However, it is crucial to determine whether these commodities may contain residues of any major food allergens or have been subjected to any treatments that may introduce allergens, which would necessitate appropriate labeling as per the Food Allergen Labeling and Consumer Protection Act of 2004 (FALCPA) and FDA policies.\n\nIn summary, the extent of the labeling requirements for raw agricultural commodities, such as fresh fruits and vegetables, under the food allergen labeling requirements of the FD&C Act varies based on the presence of major food allergens and the potential allergenic nature of the commodities. It is advisable for stakeholders to consider the specific details within the aforementioned guidance documents and relevant regulations for a comprehensive understanding of the labeling requirements for raw agricultural commodities.", "Based on the provided contexts, the question about whether foreign clinical study sites in a multinational study that includes domestic sites must be conducted under an IND aligns with the regulations and guidelines outlined in the \"FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND- Frequently Asked Questions Guidance for Industry and FDA Staff.\" This guidance addresses the acceptance of foreign clinical studies and the requirements for conducting such studies in compliance with Good Clinical Practice (GCP) standards, which are relevant to the question about the appropriate conduct of multinational studies.\n\nThe specific guidance on the interrelationship and interaction between the research sponsor, clinical investigator, and Institutional Review Board (IRB) is important for understanding the oversight and responsibilities related to conducting clinical trials both domestically and internationally. Additionally, the guidance on using a centralized IRB review process in multicenter clinical trials is relevant as it provides insight into the considerations and requirements for reviewing research conducted at multiple sites, including international locations.\n\nFurthermore, the guidance on non-local IRB review is pertinent as it addresses the circumstances under which local review by an IRB may not be available, offering insights into the responsibilities and procedures regarding non-local IRB oversight of research activities, including those conducted in foreign locations as part of multinational studies.", "Based on the regulatory context provided, the most relevant insights for the recommendations for stability testing data of modified release dosage forms can be drawn from the ICH Q1A(R2) Stability Testing of New Drug Substances and Products and the Guidance for Industry on Refuse-to-Receive Standards for ANDA Submissions. Stability testing data is based on the following principles and considerations:\n\n1. Stability Testing Protocols: Protocols for stability testing should describe the type of product being tested, sampling process, duration and frequency of testing, storage conditions, methods of analysis, and other tests. The protocols should be submitted for comment before initiating permanent studies as part of the NADA or ANDA submissions.\n\n2. Evaluation of Reversibility: It is essential to establish the potential for reversibility of toxicity, especially if there is severe toxicity at clinically relevant exposures. However, demonstration of full reversibility is not considered essential. A trend towards reversibility and scientific assessment predicting eventual full reversibility are generally sufficient.\n\n3. Selection of Batches for Stability Testing: Data from formal stability studies should be provided on at least three primary batches of the drug substance, manufactured to a minimum of pilot scale using a method that simulates the final process. The overall quality of the batches should be representative of material to be made on a production scale.\n\n4. Container Closure System: Stability studies should be conducted on the drug substance packaged in a container closure system that simulates the proposed packaging for storage and distribution.\n\n5. Specification and Testing Frequency: Stability studies should include testing of attributes susceptible to change during storage, covering physical, chemical, biological, and microbiological attributes. The frequency of testing should be sufficient to establish the stability profile of the drug substance.\n\n6. Storage Conditions: Drug substances should be evaluated under storage conditions (with appropriate tolerances) that test their thermal stability and sensitivity to moisture. Long-term, accelerated, and intermediate storage conditions are detailed, based on the characteristics of the drug substance.\n\n7. Stability Commitment: If the available long-term stability data on primary batches do not cover the proposed retest period, a commitment should be made to continue the stability studies post-approval to establish the retest period firmly.\n\nIt's important to note that these recommendations are based on the provided guidance and should be considered in conjunction with specific regulatory requirements and statutory provisions when applicable.", "According to the Small Entity Compliance Guide- Revision of the Nutrition and Supplement Facts Labels, for dietary supplements, the following nutrients are required to be listed in the \"Supplement Facts\" panel: total calories, calories from fat, total fat, saturated fat, cholesterol, sodium, total carbohydrate, dietary fiber, sugars, protein, vitamin A, vitamin C, calcium, and iron. Additionally, trans fat, polyunsaturated fat, monounsaturated fat, soluble fiber, insoluble fiber, sugar alcohol, and other carbohydrates may also be declared when a claim is made about them. Furthermore, for dietary ingredients for which no daily values have been established, they must be listed by their common or usual names, and it must be indicated that no Daily Values have been established for these ingredients.\n\nIt is important to note that the information provided in this response is based on the specific regulatory guidelines outlined in the Small Entity Compliance Guide for the Revision of the Nutrition and Supplement Facts Labels.", "In order to adequately characterize the safety and efficacy of a drug for a marketing application in line with the E7 Studies in Support of Special Populations- Geriatrics, it is important to ensure an appropriate representation of the geriatric population in the clinical development program. This includes enrolling geriatric patients with concomitant therapies and co-morbidities in the clinical studies to allow for comparisons with the non-geriatric population. The guidance emphasizes the preference for including both non-geriatric and geriatric patients in the same studies, as this can facilitate the observation of age-related differences. Efforts should be made to include geriatric patients using concomitant therapies and with co-morbidities in the premarketing clinical development program.\n\nIt is important to note that when assessing reversibility in toxicity studies, the potential for reversibility should be considered, and it is generally not essential to demonstrate full reversibility. Rather, a trend towards reversibility and a scientific assessment that this trend would eventually progress to full reversibility are typically sufficient. However, if a study of reversibility is deemed necessary, it should be available to support clinical studies of a duration similar to those at which the adverse effects were seen nonclinically. Additionally, the assessment of reversibility in toxicity studies should be considered when there is severe toxicity at clinically relevant exposures, and when significant reduction in organ function is expected.\n\nOverall, the guidance recommends comprehensive evaluation and representation of the geriatric population in clinical studies to ensure the characterization of safety and efficacy for a marketing application, while also considering the potential for reversibility of toxicity in nonclinical studies.", "In accordance with the \"Labeling for Biosimilar Products Guidance for Industry,\" if a non-U.S.-licensed product is proposed for importation and use in the United States in a clinical investigation intended to support licensure of a proposed product under section 351(k), which includes bridging clinical PK and/or PD study, a separate IND may be required for the non-U.S.-licensed product. The context provided in the given scenarios is highly focused on the scientific considerations in demonstrating biosimilarity to a reference product. The discussion touches upon the complexities of protein products, manufacturing process considerations, approaches to developing and assessing evidence to demonstrate biosimilarity, and compliance policy for requirements related to labeling. However, none of these contexts directly address the specific regulatory requirement for a separate IND for a non-U.S.-licensed product in the given scenario. Therefore, to provide a precise answer, it is crucial to consult the specific regulations and guidelines related to investigational new drug applications (IND) for this situation.", "As per the context provided from the CVM GFI #156 \"Comparability Protocols - Chemistry, Manufacturing, and Controls Information for New Animal Drugs,\" the relevant regulatory guidelines for the submission of documentation in applications for parametric release of human and veterinary drug products terminally sterilized by moist heat processes are sourced from the CMC guidance document entitled \"Submission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes\" by the U.S. Department of Health and Human Services, Food and Drug Administration, CDER, CVM, and CBER in February 2010.\n\nThe guidance provides recommendations to applicants for information submission to support parametric release for sterile products terminally sterilized by moist heat when submitting a new drug application (NDA), abbreviated new drug application (ANDA), new animal drug application (NADA), abbreviated new animal drug application (ANADA), biologics license application (BLA), or supplement or other postmarketing report.\n\nThe guidance specifies that the information to be included in the submission for parametric release process should cover the following:\n\n- A citation to a complete and detailed description of the current relevant terminal sterilization cycle.\n- Identification of the critical process parameters for the product(s) proposed for parametric release, including the minimum and maximum limits for these critical parameters.\n- Acknowledgement that adherence to the critical parameters of the parametric release program will substitute for the performance of a sterility test as the primary release criterion for the product, and that sterility test results from the finished product will not be used to overrule any failure to meet the acceptance criteria of the parametric release program.\n- Documentation of the control system to verify exposure of the load to the sterilization process.\n\nThe guidance also addresses risk assessment, process understanding, and prior knowledge, recognizing these as critical elements for the submission of documentation in support of parametric release.\n\nTherefore, referring to the CMC guidance document \"Submission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes\" from the U.S. FDA would provide appropriate and relevant regulatory guidelines for the submission of documentation in applications for parametric release of human and veterinary drug products terminally sterilized by moist heat processes.", "The information you have provided is not directly related to the context of regulatory guidelines for PMA applications. To clarify, a premarket approval (PMA) application is a submission to the FDA required for receiving approval to market a new medical device. It is the agency's approval of the PMA that allows the device to be marketed in the United States. The PMA application must contain sufficient valid scientific evidence to reasonably assure that the device is both safe and effective for its intended use. The PMA includes sections containing technical data, non-clinical laboratory studies, and clinical investigations, among other elements.\n\nIf you have any specific questions or require further information on this topic or its related regulatory guidelines, please provide more context or specific details related to the regulatory aspects of PMA applications, and I would be happy to assist you further.", "The most relevant context to finding regulatory guidelines related to animal bedding is the Current Good Manufacturing Practice (CGMP) for Animal Cells, Tissues, and Cell- and Tissue-Based Products guidance for industry provided in the context titled \"CVM GFI #253 Current Good Manufacturing Practice for Animal Cells, Tissues, and Cell- and Tissue-Based Products.\" This guidance is concerned with CGMP requirements specific to the manufacturing process of animal cells, tissues, and cell- and tissue-based products, aligning with the pharmaceutical and manufacturing regulations often applicable to animal bedding.\n\nHowever, animal bedding is not explicitly addressed in the information provided. If you are looking for specific guidelines related to animal bedding, it would be recommended to contact the relevant FDA office responsible for this area or to consult with subject matter experts who specialize in animal bedding.", "You can submit written comments related to the \"Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations\" via the following methods:\n\n1. Online Submission: Visit the regulations.gov website, specifically the docket pages for the respective guidelines. For example, for the \"Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations,\" the specific URL to submit comments online would be https://www.regulations.gov/docket/FDA-1997-D-0056. Alternatively, you can access the respective docket page for the guidelines you wish to comment on.\n\n2. Mail: If unable to submit comments online, written comments can be mailed to the following address:\n\nDockets Management\nFood and Drug Administration\n5630 Fishers Lane, Rm 1061\nRockville, MD 20852\n\nAll written comments should be clearly identified with the document's docket number (e.g., FDA-1997-D-0056 for the \"Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations\").\n\nIt's important to ensure that your comments are properly identified with the relevant docket number to ensure they are associated with the correct document.", "Based on the given context, the question about determining unexpired orphan exclusivity for an indication for which the reference product is licensed seems to be unrelated to the information provided. The context appears to focus on packaging, product identification, and requirements related to pharmaceutical distribution. Therefore, I can provide a general answer to the question outside of the given context.\n\nOn that note, to determine whether there is unexpired orphan exclusivity for an indication for which the reference product is licensed, a prospective biosimilar applicant must review the current regulatory status and exclusivity information pertaining to the reference product. This can typically be done by consulting the FDA's Orange Book, which provides information on approved drug products and their associated patents and exclusivity. Additionally, the applicant may need to communicate directly with the FDA to ensure accurate and up-to-date information in this regard.", "The term \"intermediate-sized packages\" refers to packages ranging from 12 to 40 square inches of total surface area available to bear labeling. For supplements in intermediate-sized packages, the \"Supplement Facts\" panel must use type size no smaller than 6 point, except that type no smaller than 4.5 point may be used under specific circumstances, such as when there are more than 16 dietary ingredients listed in packages with 20 to 40 square inches, or more than 8 dietary ingredients listed in packages with less than 20 square inches available for labeling. Additionally, products in intermediate-sized packages may use a tabular or linear format for the \"Supplement Facts\" panel, and abbreviations may be used in the panel for small and intermediate-sized packages. The use of hairlines is not always required on labels of intermediate-sized packages; a row of dots connecting the columns containing the name of each dietary ingredient and the quantitative amount may be used if space is limited and the minimum type size requirement is met.\n\nThese regulations are found in the Code of Federal Regulations (CFR) Title 21, specifically in sections 101.36(i)(2)(ii), 101.36(e)(9), and 101.36(i)(2)(v), and they provide detailed guidance on the specific requirements for supplement labeling on intermediate-sized packages. Compliance with these requirements is essential for manufacturers and distributors of dietary supplements to ensure that their labeling is in accordance with the regulatory guidelines.\n\nIf there are specific questions related to the application of these regulations or the compliance requirements for intermediate-sized packages, it is recommended to consult directly with the FDA for further clarification and assistance.", "In the context of the given question and relevant content from the ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals, \"data to support a rationale for the combination study\" includes the need to provide data that supports the rational for the combination of multiple entities for the intended clinical study. The data should be based on a combination toxicity study intended to address a specific toxicological concern derived from the experience with the individual agents. This study should be of a duration appropriate to assess the concern and should incorporate endpoints to evaluate additive and synergistic effects for known toxicities predicted from the pharmacological, toxicological, and pharmacokinetic profiles of the individual entities. Additionally, the available clinical data and standard endpoints typically used in a general toxicity study should be considered in the combination toxicity study.\n\nThe sponsor should also consider the factors, such as the choice of species, dosing frequency justifications, and appropriate dosages, to address the identified toxicological concern. It is important to note that combination toxicity studies are generally recommended for combinations involving no more than two entities initially, with further testing considered on a case-by-case basis and in consultation with appropriate regulatory authorities. Overall, the combination toxicity study should provide the necessary data to support the rationale for the combination study by addressing potential toxicological concerns associated with the use of multiple entities.", "A product identifier under the Drug Supply Chain Security Act (DSCSA) is defined in section 581(14) of the FD&C Act as a standardized graphic that includes the product's standardized numerical identifier (composed of the NDC and a unique alphanumeric serial number), lot number, and expiration date, in both human- and machine-readable formats. The machine-readable format must be on a data carrier that conforms to the standards developed by a widely recognized international standards development organization.\n\nUnder section 582(b)(2)(A) of the FD&C Act, manufacturers are required to \"affix or imprint a product identifier to each package and homogenous case of a product intended to be introduced in a transaction into commerce\" beginning no later than November 27, 2017. Repackagers are required to do the same no later than November 27, 2018.\n\nThe product identifier data is specifically required under section 582(a)(9) of the FD&C Act to be in a \"2-dimensional data matrix barcode\" for packages and in a \"linear or 2-dimensional data matrix barcode\" for homogenous cases, which can be verified using \"human-readable or machine-readable methods.\"\n\nThe product identifier is a critical component of complying with the Drug Supply Chain Security Act, and its proper implementation is essential for enhancing the tracing of prescription drugs through the pharmaceutical distribution supply chain.", "Based on the provided contexts related to the FDA Decisions for Investigational Device Exemption (IDE) Clinical Investigations, the non-significant risk (NSR) device studies are those that do not meet the criteria for significant risk (SR) device studies. The determination of whether a device study is NSR or SR is a crucial aspect of regulatory assessment. An NSR study is one that does not present a potential for serious risk to the health, safety, or welfare of the subject, as defined under 21 CFR 812.3(m), and does not meet the criteria for an SR study established by the FDA.\n\nIn the context provided, it is essential for sponsors to make the initial risk determination and present it to the Institutional Review Board (IRB). The FDA is available to assist the sponsor, clinical investigator, and IRB in making the risk determination, and the IRB must review the sponsor's determination for every investigational medical device study reviewed and modify the determination if it disagrees with the sponsor. Final determination of whether a device study is significant or non-significant risk rests with the FDA once an IDE is submitted or if asked by the sponsor, clinical investigator, or IRB.\n\nThe major differences between SR and NSR studies relate to the IDE approval process, sponsor's record-keeping and reporting requirements, and the ability to commence the study. While SR studies require FDA approval before proceeding, NSR studies follow abbreviated requirements under 21 CFR 812.2(b). This guidance is vital in providing a framework for assessing benefits and risks of IDE applications throughout all stages of device development as this influences the decision-making process for IDE applications.\n\nIn summary, the assessment of NSR device studies is an essential part of the FDA's regulatory process, impacting the IDE approval process, study design considerations, and ultimately determining whether a study qualifies as NSR or SR. It also considers the benefits and risks associated with clinical investigational device use proposed in IDE applications.", "In considering the provided contexts, there is no direct guidance dictating the extent to which computer programs should be documented as standard operating procedures (SOPs). However, specific elements of the contexts can be related to the documentation of computer programs within the pharmaceutical manufacturing environment and compliance with regulatory requirements.\n\nUnder a quality system approach, thorough documentation of computer programs that are utilized to record, analyze, or control manufacturing processes is essential. This documentation should encompass the specific details of the computer program's intended use, operational parameters, and any associated SOPs relevant to its functioning. It is important to ensure that computer programs used for monitoring, measurement, and analysis of operations adhere to the established quality system procedures and meet the requirements outlined in the Current Good Manufacturing Practice (CGMP) regulations.\n\nAdditionally, validation of computer programs intended for use in CGMP workflows is crucial to ensure their compliance with regulatory requirements. The extent of validation studies should be commensurate with the risk posed by the automated system, and specific validation activities should be conducted to demonstrate the accuracy and performance of the computer program in achieving the desired outcomes within the manufacturing process.\n\nFurthermore, strict controls on access to CGMP computer systems are essential to maintain data integrity and ensure compliance with CGMP regulations. Access to these systems should be restricted to authorized personnel, and appropriate controls should be implemented to prevent unauthorized modifications to records and data. Shared login accounts for computer systems are discouraged, and proper measures should be implemented to ensure that actions in the system are attributable to specific individuals, as required by CGMP regulations.\n\nIn conclusion, while there may not be a specific guideline outlining the extent to which computer programs should be documented as SOPs, a comprehensive approach to the documentation, validation, and control of computer programs within the pharmaceutical manufacturing environment is necessary to ensure compliance with CGMP regulations and the principles of a quality system approach.", "In the context of \"FDA Decisions for Investigational Device Exemption Clinical Investigations Guidance for Sponsors, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff,\" the relevant statutes and regulations that apply to medical device clinical investigations are detailed in 21 CFR Part 812. This regulation contains provisions that govern the conduct of clinical investigations of devices to determine their safety and effectiveness, as well as outlines the responsibilities of sponsors, clinical investigators, institutional review boards, and the FDA regarding the initiation, conduct, and approval of investigational device exemption (IDE) studies.\n\nFDA approval of an IDE submission allows the initiation of subject enrollment in a clinical investigation of a significant risk device, as defined in 21 CFR 812.3(m). The statute further specifies the situations in which FDA cannot disapprove an IDE application, as outlined in Section 520(g)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).\n\nIn addition to 21 CFR Part 812, other relevant guidance documents have provided further interpretations and detailed considerations for benefit-risk determinations and design considerations for pivotal clinical investigations for medical devices. These include guidelines for making benefit-risk assessments, informing the sponsor of recommended modifications to the study design, assessing risks and benefits, and ensuring the informed consent process is adhered to, as stipulated in 21 CFR Part 50.\n\nMoreover, the document \"Design Considerations for Pivotal Clinical Investigations for Medical Devices Guidance for Industry, Clinical Investigators, Institutional Review Boards, and FDA Staff\" provides additional principles and recommendations for conducting pre-market clinical studies pivotal in establishing the safety and effectiveness of medical devices.\n\nThese regulations and guidance documents collectively provide the legal framework and guidelines for the conduct and assessment of medical device clinical investigations in the U.S.", "In response to the question about submitting information regarding the tertiary packaging site to the agency and whether CDER can be notified in an annual report, the most relevant guidance from the provided contexts is \"Changes to an Approved NDA or ANDA; Specifications - Use of Enforcement Discretion for Compendial Changes Guidance for Industry.\"\n\nBased on this guidance, when it comes to the specifics of tertiary packaging sites and the requirement to submit such information to the agency or notify CDER, the guidance primarily focuses on the submission requirements for specifications changes, including compendial changes. It does not explicitly address the tertiary packaging site's reporting requirement or its inclusion in an annual report.\n\nAs such, this particular guidance does not directly provide detailed information about the specific requirements for reporting tertiary packaging site changes. Therefore, it may be necessary to seek additional or specific guidance related to tertiary packaging sites and their reporting requirements from other relevant FDA's official guidances or consult directly with the appropriate FDA staff.\n\nFor more specific information about reporting tertiary packaging site changes and annual report notifications, it would be advisable to review the FDA's guidance documents or contact the FDA staff responsible for implementing the relevant regulations pertaining to tertiary packaging site reporting.", "In the context of the provided regulatory guidelines, particularly \"Content and Format of the Nonclinical Pharmacology:Toxicology Section of an Application\" and \"Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route,\" the assurance that study pathologist's diagnoses and interpretations are free from undue influence during the pathology peer-review process can be facilitated through various key measures. These measures include ensuring thorough documentation of the nonclinical safety assessment studies, such as the pharmacodynamic and toxicology studies, particularly involving the route of administration, dose levels or concentrations of the test substance, and the duration of studies.\n\nFurthermore, it is essential that the integrated overview and conclusions in the nonclinical pharmacology and toxicology section provide logical, well-argued conclusions supporting the safety of the product for the intended clinical use. This involves presenting information in a systematic manner with a focus on the needs of regulatory authority assessors. Additionally, a comprehensive evaluation of toxicology studies should be provided, ensuring a clear and well-integrated discussion of the implications of the nonclinical findings for the safe human use of the pharmaceutical.\n\nMoreover, it is important for the studies to include a terminal non-dosing period, especially when there is severe toxicity at clinically relevant exposures or when toxicity becomes detectable at an advanced stage of the pathophysiology in humans.\n\nOverall, adherence to these guidelines and best practices should ensure that the study pathologist's diagnoses and interpretations remain objective and free from undue influence during the pathology peer-review process, thus promoting the integrity of the nonclinical safety assessment studies.", "A National Drug Code (NDC) is a unique identifier given to each drug product in the United States. It consists of a three-segment number that identifies the labeler or vendor, the product, and the commercial package size. The NDC serves as a universal product identifier for human drugs in the United States, facilitating tracking, tracing, and verification throughout the supply chain. The NDC is required to be affixed or imprinted on each package and homogenous case of a drug product intended for transaction into commerce, per the requirements of the Drug Supply Chain Security Act. Manufacturers are required to affix or imprint a product identifier, which includes the NDC, a unique serial number, lot number, and expiration date, in both human- and machine-readable formats on each package and homogenous case of a drug product. The FDA has provided compliance policy guidance related to these product identifier requirements, outlining the implementation and enforcement policies.", "In the context of the given regulatory guidelines in the question related to the declaration of small amounts of nutrients and dietary ingredients on nutrition labels, the step 4 for calculating the amount of added sugars from a juice ingredient in a multi-ingredient formulation is as follows:\n\nStep 4:\nDetermine the amount of sugars from the juice ingredient that are in excess of what would be expected from the same volume of 100 percent fruit or vegetable juice of the same type. The excess sugars contributed by the juice ingredient must be declared as added sugars on the label, as required by the Nutrition Facts label final rule.\n\nAdditionally, it may be necessary to consider factors such as the total moisture content of the finished product, the Brix values, and the weight basis for declaring the amount of added sugars, as outlined in the relevant guidance and industry recommendations.\n\nPlease note that this step should be interpreted and implemented in accordance with the specific guidance and regulations applicable to the declaration of added sugars on nutrition labels in the given context.", "Based on the information provided from the \"Interpretation of the 'Deemed to be a License' Provision of the Biologics Price Competition and Innovation Act of 2009 Guidance for Industry,\" the holder of an approved NDA for a biological product on the FDA's list needs to take affirmative steps for its NDA to be deemed a BLA per section 7002(e)(4) of the Biologics Price Competition and Innovation Act (BPCI Act). The provision specifically states that an approved application for a biological product under section 505 of the FD&C Act shall be deemed to be a license for the biological product under section 351 of the Public Health Service Act (PHS Act) on the date that is 10 years after the date of enactment of the BPCI Act.\n\nTherefore, it is important for the holder of an approved NDA for a biological product to understand that their approved NDA will be deemed a BLA on the designated transition date, and this transition will replace the NDA with an approved BLA under section 351 of the PHS Act. It is pertinent for holders of approved NDAs for biological products to be aware of this transition and the implications it will have on the status of their NDA. Additionally, it is important for them to adhere to the regulatory requirements and guidance provided by the FDA in relation to this transition, including any administrative actions and considerations associated with the transition, as outlined in FDA's relevant guidance documents.\n\nIt is recommended that holders of approved NDAs for biological products engage with the FDA, where feasible and appropriate, to gain a clear understanding of the transition process and any implications it may have on their specific products. Furthermore, they should proactively address any pending supplements or amendments to their NDA that may be affected by the transition to ensure compliance with the regulatory requirements and timelines associated with the transition of their NDA to a deemed BLA.", "Based on the information provided in the contexts given, we will focus on the core theme related to good manufacturing practices and the regulatory process for assessing and addressing changes in manufacturing processes. It is important to note that the issuance of Form FD-483, also known as a Notice of Inspectional Observations, is part of the regulatory process related to good manufacturing practices. The issuance of this form typically occurs during an inspection when the FDA has observed conditions that may constitute violations of the Food, Drug, and Cosmetic Act and require corrective action.\n\nThe specific procedure for the issuance of a Form FD-483 involves FDA investigators documenting any observations of non-compliance with current good manufacturing practices during an inspection. These observations are then detailed in the Form FD-483, which is provided to the inspected facility at the conclusion of the inspection. The facility is then typically required to provide responses and corrective action plans for the observations documented in the Form FD-483.\n\nIn the context provided, there is extensive information on the requirements and processes related to demonstrating compliance with current good manufacturing practices, the assessment of manufacturing changes, and the regulatory requirements for documenting and reporting changes to approved drug applications. This includes detailed guidance on assessing the effects of manufacturing changes, conformance to specifications, equivalence comparisons, and addressing adverse effects resulting from manufacturing changes.\n\nThe information provided in the contexts focuses on the regulatory and compliance aspects of manufacturing changes, including the need for conducting assessments, maintaining compliance with good manufacturing practices, and reporting changes to approved applications. Therefore, the specific procedure for the issuance of a Form FD-483 may not be explicit in the provided information, but it is clear that compliance with good manufacturing practices is a fundamental aspect of the regulatory guidelines referenced.\n\nIt is important to consult the specific regulatory guidelines and seek guidance from regulatory experts or legal counsel when addressing the issuance of Form FD-483 and the related regulatory processes. These professionals can provide detailed insights and guidance tailored to the specific circumstances and regulatory requirements.", "In accordance with the details from the Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients (APIs), acceptance criteria for residues should be defined for dedicated equipment. The guideline emphasizes the importance of validation of cleaning procedures and reflects the actual equipment usage patterns. It recommends the selection of representative intermediate or API for cleaning validation based on solubility, difficulty of cleaning, and calculation of residue limits based on potency, toxicity, and stability. The protocol for cleaning validation should describe the equipment to be cleaned, procedures, materials, acceptable cleaning levels, parameters to be monitored and controlled, and analytical methods. Additionally, validated analytical methods with sufficient sensitivity to detect residues or contaminants should be used. The detection limit for each analytical method should be sufficiently sensitive to detect the established acceptable level of the residue or contaminant. The residue limits should be practical, achievable, verifiable, and based on the most deleterious residue. Furthermore, equipment cleaning/sanitization studies should address microbiological and endotoxin contamination if there is a need to reduce total microbiological count or endotoxins in the API.", "In the context of \"Small Entity Compliance Guide- Revision of the Nutrition and Supplement Facts Labels\", if dietary supplements are sold from bulk containers, the \"Supplement Facts\" nutrition information panel must still be provided even for products sold in bulk. The information panel should contain the \"Supplement Facts\" panel, the ingredient list, and the name and place of business of the manufacturer, packer, or distributor, unless these are already included on the principal display panel. It is important to ensure that the \"Supplement Facts\" panel is presented using a single easy-to-read type style, with clear type size and easy-to-read font, and properly separated dietary ingredients using hairlines or other appropriate methods to ensure clear presentation and readability for consumers.  It is also essential to ensure that compliance with nutrition labeling requirements is in line with the regulatory standards, including the specified type size, type style, and other formatting guidelines mentioned in the context documents.\n\nThe Dietary Supplement Health and Education Act of 1994 (DSHEA) allows for certain exemptions from nutrition labeling requirements for dietary supplements, including when products are sold in bulk form and are not distributed to consumers in such form. In such cases, the product is exempted from having a \"Supplement Facts\" panel. However, if the dietary supplement is supplied for use in the manufacture of other dietary supplements, the exemption may not apply. It is important to review and comply with the specific exemption criteria outlined in the regulations to determine if the exemption from nutrition labeling requirements applies to the specific situation of selling dietary supplements from bulk containers.\n\nIn summary, when providing the \"Supplement Facts\" panel for dietary supplements sold from bulk containers, it is essential to ensure compliance with the formatting and presentation requirements outlined in the relevant regulations, as well as to consider any applicable exemptions based on the specific circumstances of selling dietary supplements in bulk form.", "As per the given context, specifically referring to the ICH Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, it is mentioned that a retrospective approach to validation is still acceptable, particularly for well-established processes that have been used without significant changes to the API quality due to changes in raw materials, equipment, systems, facilities, or the production process. The validation approach may be utilized if critical quality attributes and process parameters have been identified, appropriate in-process acceptance criteria and controls have been established, no significant process/product failures unrelated to operator error or unsuitable equipment have occurred, and impurity profiles have been established for the existing API.\n\nIt is stated that batches selected for retrospective validation should be representative of all batches made during the review period, including any batches that failed to meet specifications, and should be sufficient in number to demonstrate process consistency. Additionally, the number of process runs for retrospective validation should depend on the complexity of the process or the magnitude of the process change being considered. Generally, data from ten to thirty consecutive batches should be examined to assess process consistency, but fewer batches can be examined if justified.\n\nIn conclusion, the retrospective approach to validation is considered still acceptable, provided that the specific criteria outlined - related to critical attributes, in-process controls, process consistency, and impurity profiles - are met. This information is based on the context provided and the relevant sections from the ICH Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients.", "In the context of the \"Guidance for Industry- Interim Procedures for Qualified Health Claims in the Labeling of Conventional Human Food and Human Dietary Supplements,\" the term \"recognized antioxidant activity\" refers to the scientifically acknowledged capability of a substance to act as an antioxidant, providing specific benefits related to neutralizing free radicals and reducing oxidative stress. The guidance provides criteria for evaluating substances with antioxidant activity to support qualified health claims. The assessment of recognized antioxidant activity plays a crucial role in evaluating the potential health benefits associated with the substance, particularly when considering its use in qualified health claims for conventional human food and dietary supplements.", "Based on the given context, the question regarding the definition of \"product class\" for determining whether an application for a biological product may be submitted under section 505 of the FD&C Act during the transition period is directly related to the \"The Deemed to be a License\" Provision of the BPCI Act. This provision states that an application for a biological product may be submitted under section 505 of the FD&C Act not later than a specified date if the biological product is in a product class for which a biological product in such product class was approved under section 505 of the FD&C Act not later than a specific earlier date.\n\nIn the given context, the guidance resources from the FDA are most relevant for addressing the question. The specific guidance provided for the transition period and the deemed to be a license provision of the BPCI Act contains detailed information about the requirements and conditions for submitting applications for biological products during the transition period. This guidance outlines the criteria for determining whether a biological product falls within a product class that qualifies for submission under section 505 of the FD&C Act during the transition period.\n\nTherefore, to answer the question, I recommend referring to the specific guidance provided by the FDA on the deemed to be a license provision of the BPCI Act, which includes detailed information about the product class criteria and the submission requirements during the transition period.", "In line with the information provided in the context from ICH Q11 Development and Manufacture of Drug Substances, the application for a starting material that is a commercially available chemical should include a justification for how the proposed starting material is appropriate based on the general principles for the selection of starting materials outlined in the guideline. This justification should consider factors such as the ability of analytical procedures to detect impurities in the starting material, the fate and purge of impurities in subsequent processing steps, and how the proposed specification for the starting material will contribute to the control strategy. The applicant generally need not justify the use of a commercially available chemical as a starting material, provided it meets the criteria of being sold as a commodity in a pre-existing, non-pharmaceutical market in addition to its proposed use as a starting material. The application should also include a flow diagram outlining the synthetic route for the manufacture of the drug substance, with the proposed starting materials clearly indicated. Additionally, the specification for the commercially available starting material should be provided, along with information on any additional purification steps if necessary to ensure consistent quality. If the chemical is considered to have a significant nonpharmaceutical market, additional recommendations and documentation apply, as detailed in the context provided.", "As per the ANDAs- Stability Testing of Drug Substances and Products guidelines, if one among the three batches in accelerated conditions shows a significant change, it's crucial to conduct a thorough investigation. Any confirmed significant change or Out of Specification (OOS) result should be immediately reported to the relevant competent authorities, considering the potential impact on batches already on the market. The stability studies should include testing the attributes of the drug substance that are susceptible to change during storage and likely to influence quality, safety, and/or efficacy. The testing should cover physical, chemical, biological, and microbiological attributes. Additionally, the storage conditions and the lengths of studies chosen should be sufficient to cover storage, shipment, and subsequent use.\n\nIf significant change occurs within the first 3 months' testing at the accelerated storage condition, a discussion should be provided to address the effect of short-term excursions outside the label storage condition (e.g., during shipping or handling). This discussion can be supported, if appropriate, by further testing on a single batch of the drug substance for a period shorter than 3 months but with more frequent testing than usual.\n\nIn cases of any significant changes or OOS results, it's important to follow Good Manufacturing Practice (GMP) principles and thoroughly document the investigations and justifications for any alternative testing procedures, deviations, or proposed changes in accordance with the Pharmaceutical Quality System (PQS) and appropriate regulatory guidelines.\n\nFurthermore, a risk management approach should be used to define appropriate stability strategies, and any potential product-specific stability test conditions and methods in the stability protocol should be justified. It's also important to consider stability-related considerations throughout the product supply chain, including excursions during storage and transportation, freeze-thaw cycle stability, and processing and hold-time studies during manufacture.\n\nFinally, there should be a commitment made to continue stability studies post-approval to firmly establish the retest period when available long-term stability data on primary batches do not cover the proposed retest period granted at the time of approval.", "Based on the provided contexts and the focus on the Small Entity Compliance Guide- Revision of the Nutrition and Supplement Facts Labels, the question about the unique aspects of ingredient labeling of dietary supplements pertains to the specific requirements and considerations outlined in this guidance.\n\nIn the context of the \"Small Entity Compliance Guide on Structure:Function Claims,\" the unique element of ingredient labeling for dietary supplements is related to the permissible structure/function statements and the distinction between structure/function claims and disease claims. This guide primarily focuses on the legal requirements for labeling claims for dietary supplements, including the permitted structure/function statements and the criteria that define disease claims. These requirements pertain to the types of claims that can be made for dietary supplements and the substantiation needed for these claims.\n\nIn the \"Nutrient Requirements for Supplement Facts Labels\" context, the unique aspect of ingredient labeling of dietary supplements involves the differences in content and format between the Supplement Facts label and the Nutrition Facts label. The guidance outlines specific differences in the ordering of vitamins and minerals on the Supplement Facts label, as well as the compliance requirements and level of variance allowed for various nutrients.\n\nThe \"FDA's Policy on Declaring Small Amounts of Nutrients and Dietary Ingredients on Nutrition Labels: Guidance for Industry\" context presents the unique consideration of the caloric value of allulose and its declaration on Nutrition and Supplement Facts labels. The guidance addresses the FDA's intent to exercise enforcement discretion for the exclusion of allulose from the amount of \"Total Sugars\" and \"Added Sugars\" declared on the label and provides recommendations for the caloric value of allulose, highlighting the specific scientific evidence and considerations related to the declaration of allulose on labels.\n\nThe \"Guidance for Industry- Labeling OTC Human Drug Products\" context outlines specific requirements and considerations for the labeling of over-the-counter (OTC) human drug products, including the mandatory content, format, and specific information for each heading in the Drug Facts labeling.\n\nIn summary, the unique aspects of ingredient labeling for dietary supplements, as outlined in different guidance contexts, encompass specific requirements, considerations, and distinctions related to permissible claims, nutrient content, caloric value, and the mandatory content and format of the labels. These unique elements are crucial for ensuring compliance and accurate representation of dietary supplement ingredients on labels.", "In accordance with the information provided by the Prescription Drug Marketing Act (PDMA) Requirements - Questions and Answers document, when an ADR drop ships on behalf of a non-ADR directly to the pharmacy or customer, it is important for the non-ADR seller to provide a pedigree to the purchaser, according to 21 CFR SS 203.50. This requirement applies to the transmission of the drugs and necessitates the inclusion of information regarding each prior sale, purchase, or trade of the product. It is important to adhere to these requirements to ensure compliance with the PDMA. Furthermore, the document emphasizes the significance of retaining the pedigree for 3 years for both ADRs and non-ADRs involved in the distribution of the drug product, as outlined in 21 CFR SS 203.60.", "Based on the provided context from the S9 Nonclinical Evaluation for Anticancer Pharmaceuticals, if the initial assessment of phototoxic potential based on physicochemical properties indicates a phototoxic risk, nonclinical photosafety studies should be conducted as follows:\n\nThe initial assessment of phototoxic potential should be performed prior to Phase 1 and should be based on the photochemical properties of the drug and information on other members in the class. If the assessment indicates a potential risk for phototoxicity, appropriate protective measures should be taken during outpatient trials.\n\nNonclinical photosafety assessments consistent with the principles described in ICH M3(R2) should be provided prior to marketing if the photosafety risk cannot be adequately evaluated based on nonclinical data or clinical experience.\n\nThe assessment strategies outline various options for collecting human data, ranging from standard reporting of adverse events in clinical studies to a dedicated clinical photosafety trial, with the precise strategy determined on a case-by-case basis.\n\nIt is important to note that the assessment of reversibility is not always critical to conclude whether an adverse effect is reversible. In cases where significant risk for phototoxicity is indicated, appropriate nonclinical and/or clinical photosafety assessment of the substance should be conducted. If the nonclinical assessment indicates potential phototoxicity, protective measures and appropriate photosafety evaluation should be undertaken before exposure of large numbers of subjects.", "Based on the information from the provided context, it seems that the reprocessing of components or product, as mentioned in CVM GFI #156 Comparability Protocols for New Animal Drugs, is not directly addressed. However, based on the general regulatory guidelines in the context, reprocessing may be considered as part of the manufacturing process changes and must be thoroughly documented and justified. \n\nThe reprocessing of components or product would likely fall under the category of changes to the manufacturing process, which would require thorough evaluation of the potential impact on the quality of the intermediate or API. This could involve classification of the reprocessing as a minor or major change, scientific assessment of the need for additional testing and validation studies, evaluation of the first batches produced or tested under the change, and the potential impact on established retest or expiry dates. \n\nIn addition, any reprocessing activities must be in compliance with FDA's guidance on reprocessing of medical devices, if applicable, and should be subject to the validation methods and labeling requirements outlined in the relevant guidance.\n\nLastly, it is important to establish appropriate documentation to support the reprocessing activities, including procedures for reprocessing, reworking, recycling, regeneration, and salvaging, and the maintenance of equivalent quality of reprocessed materials.\n\nIt is important to note that specific details regarding the proposed reprocessing activities should be assessed on a case-by-case basis in accordance with the guidelines provided in the context and any relevant FDA guidance documents.", "In accordance with the guidance provided in the \"Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\" document, the GLPs (Good Laboratory Practices) do not specifically require each test article to undergo absorption studies. However, it is essential to align the testing and reporting of test articles with the principles of GLPs.\n\nThe Good Laboratory Practice (GLP) regulations emphasize the need for accurate, reliable, and reproducible nonclinical laboratory studies to support the safety of regulated products. While the specific requirements for absorption studies are not outlined in the provided context, the principles of GLPs in relation to the conduct of laboratory studies indicate the importance of ensuring the accuracy and integrity of all nonclinical studies, including absorption studies.\n\nGLPs require thorough investigations and documentation when Out-of-Specification (OOS) test results are obtained, including identifying the cause of the OOS result, maintaining written records of the investigation, as well as ensuring thorough, unbiased, and scientifically sound investigations.\n\nFurthermore, the context provided highlight various responsibilities and procedures relevant to GLPs, including the responsibilities of the analyst, the laboratory supervisor, handling of retained sample preparations, documenting investigations, and addressing frequent errors to ensure compliance with the CGMP (Current Good Manufacturing Practice) regulations.\n\nIt is important to note that GLPs apply to safety studies intended for submission to the regulatory agency in support of the approval of a regulated product. Preliminary exploratory studies, screening studies, and range-finding studies may be exempt from GLPs if appropriately labeled and intended for improving the experimental design of planned nonclinical laboratory studies.\n\nIn summary, while the specific requirement for absorption studies on each test article is not explicitly addressed in the provided contexts, it is important to conduct all nonclinical laboratory studies including absorption studies in accordance with the principles of GLPs, ensuring scientific soundness, accurate data, and compliance with regulatory guidelines.", "I'm sorry, but the information provided does not directly address the question regarding the selection of dosimeter locations for dose mapping studies in the context of \"CVM GFI #156 Comparability Protocols - Chemistry, Manufacturing, and Controls Information for New Animal Drugs.\" I recommend reaching out to the relevant regulatory agency that issued CVM GFI #156 for a specific answer to this question regarding dose mapping studies and dosimeter location selection.", "In the context of the given regulatory guidelines, I will provide an explanation of factors 2 and 3 as applied in the guidance \"Policy for Device Software Functions and Mobile Medical Applications Guidance for Industry and Food and Drug Administration Staff\".\n\nFactor 2: \"Software functions that become a regulated medical device by performing patient-specific analysis and providing specific output(s) or directive(s) to health care professionals for use in the diagnosis, treatment, mitigation, cure, or prevention of a disease or condition.\"\n\nFactor 2 describes a category of software functions that act as regulated medical devices by analyzing patient-specific data and providing specific outputs or directives to healthcare professionals. Examples cited in the guidance include computer-aided detection software for image processing, radiation therapy treatment planning software, and software that analyzes ECG waveforms to detect or diagnose arrhythmias.\n\nFactor 3: \"Software functions that transform the mobile platform into a regulated medical device by using attachments, display screens, or sensors or by including functionalities similar to those of currently regulated medical devices.\"\n\nFactor 3 applies to software functions, typically mobile apps, that transform a mobile platform into a regulated medical device by utilizing attachments, display screens, sensors, or functionalities similar to those of currently regulated medical devices. Examples provided in the guidance include mobile apps that use a built-in accelerometer to collect motion information for monitoring sleep apnea, or use attachments to measure and display blood glucose levels.\n\nThese factors illustrate the scope of software functions that are considered as regulated medical devices, ensuring that manufacturers understand the regulatory requirements associated with the classification of such devices and mobile applications.\n\nThese examples demonstrate the application of factors 2 and 3 in determining the regulatory oversight of specific software functions and mobile medical applications to ensure the safety and effectiveness of these digital health products.", "In the context of \"Assay Migration Studies for In Vitro Diagnostic Devices Guidance for Industry and FDA Staff,\" a study refers to the structured investigation, assessment, or evaluation of the performance criteria and study designs necessary to support the migration of an assay from an old system to a new system. The study should include analytical and comparison studies that demonstrate the performance of the assay on the new system compared to the previous approved/licensed/cleared system. These studies should encompass various aspects, such as performance at low analyte levels, precision, interfering substances studies, on-board reagent/calibrator and sample stability studies, carry-over or cross-contamination studies, and matrix equivalency and recovery studies. The scientific assessment may also involve reversibility studies to predict the potential reversibility of any adverse effects. The information collected from these studies is crucial for the regulatory review process to determine whether the use of the approved/licensed/cleared assay with the new system may compromise safety and effectiveness. The decision may impact the regulatory pathway, clinical trial protocols, and any necessary additional studies or submissions required for approval or clearance.", "In accordance with the guidance provided in the \"Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency,\" the FDA intends to prioritize inspections by using a risk-based approach, taking into consideration factors such as public health impact, investigator safety, travel restrictions, and product availability. Due to travel restrictions during the COVID-19 public health emergency, the FDA has been using alternative tools, including requesting existing inspection reports from trusted foreign regulatory partners, remote interactive evaluations, and the use of trusted foreign regulatory partners' inspection reports through mutual recognition agreements and other confidentiality agreements to evaluate facilities. The agency aims to continue the assessment of applications using a risk-based approach while considering all manufacturing facilities for evaluation. The need for and selection of sites for inspections, including Bioresearch Monitoring (BIMO) inspections, will continue to be risk-based, taking into account application and site-specific factors. Furthermore, FDA is willing to consider requests from applicants to submit certain changes using a lower reporting category for products in shortage or intended to address COVID-19. The agency intends to minimize, though not necessarily avoid, missing additional application goal dates due to travel restrictions during the COVID-19 public health emergency and to balance these objectives with reducing any backlog of assigned inspections. Additionally, FDA has implemented interim processes to communicate with manufacturing facilities regarding issues identified following a review of records or other information requested \"in advance of or in lieu of\" a preapproval or pre-license inspection. These approaches, along with a case-by-case determination of mission-critical inspections, demonstrate the FDA's intended approach to prioritize inspections as travel restrictions are eased or lifted.\n\nFurthermore, the guidance on the \"Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency\" outlines recommendations for remote monitoring of clinical trials when on-site visits are not possible during the COVID-19 public health emergency. This guidance demonstrates the FDA's flexibility in addressing challenges related to inspections and the conduct of clinical trials during the public health emergency.\n\nIt is important to note that the specific guidance referenced provides detailed information about the FDA's approach to prioritizing inspections, conducting remote interactive evaluations, and addressing challenges related to the COVID-19 public health emergency.", "Based on the given context, the scope of Section 13 of the PBRER (Periodic Benefit-Risk Evaluation Report) is not limited to controlled clinical trials. The main focus of the PBRER is the evaluation of relevant new safety information from available data sources placed within the context of any pertinent efficacy/effectiveness information that may have become available since the International Birth Date (IBD) or the Development International Birth Date (DIBD). This means that the information from various sources, not just controlled clinical trials, should be included in the PBRER. The PBRER is intended to provide a comprehensive evaluation of the benefit-risk profile of the medicinal product based on all available data, not limited to controlled clinical trials.", "I'm sorry, I cannot find any information regarding release profiles and how the product achieves the desired profile in the contexts provided. If you have a specific question related to regulatory guidelines or other topics, feel free to ask and I would be happy to assist you.", "Based on the provided context from the Sponsor - Investigator - IRB Interrelationship Guidance for Institutional Review Boards and Clinical Investigators, the sponsor is not required to review the consent form approved by the IRB to ensure all FDA requirements are met. This is indicated by the guidance\u2019s statement that sponsors should rely on the clinical investigator to ensure IRB compliance with regulations. The responsibility primarily falls on the clinical investigator to assure the sponsor that the IRB is functioning in compliance with the regulations. Moreover, the guidance emphasizes that the documents provided by the IRB to the sponsor, through the clinical investigator, provide reasonable assurance of IRB compliance with regulations.\n", "The guidance provided in ICH M3(R2) regarding metabolites applies to prodrugs when a metabolite provides most of the pharmacologic activity. The guidance emphasizes the importance of evaluating metabolites and their potential impact on safety to support human clinical trials and marketing authorization for pharmaceuticals. This includes considerations related to toxicology, pharmacokinetics, pharmacodynamics, and general nonclinical safety assessment.\n\nThe guidance encourages a thorough evaluation of metabolites, including their potential toxicity, pharmacological effects, and contribution to overall safety. It is important to assess the potential reversibility of toxicity associated with metabolites, particularly when severe toxicity is observed. The assessment of reversibility is critical to understanding the safety profile of the prodrug and its active metabolites.\n\nFurthermore, the guidance acknowledges the need for scientific assessment of reversibility and emphasizes that the demonstration of complete reversibility is not always essential. Instead, a trend towards reversibility and a scientific assessment indicating potential for full reversibility are generally considered sufficient. This approach allows for a holistic evaluation of the safety and pharmacological activity of prodrugs and their metabolites in the context of human clinical trials and marketing authorization.\n\nOverall, the guidance on metabolites in ICH M3(R2) is applicable to prodrugs, especially when the metabolite provides most of the pharmacologic activity. It provides a structured framework for evaluating the safety and efficacy of prodrugs and their metabolites, ensuring that thorough assessments are carried out to support the conduct of human clinical trials and marketing authorization for pharmaceuticals.", "Yes, according to the given context \"Informed Consent Guidance for IRBs, Clinical Investigators, and Sponsors\" and the specific section \"Step 2 - Obtain and Document the Subject's Informed Consent in Accordance with FDA Regulations at 21 CFR 50.20, 21 CFR 50.25 and 21 CFR 50.27 Using a Translated Short Form and the English Language Version of the Long Form as the Written Summary,\" informed consent documents must be translated into the written language native to study subjects who do not understand English. The guidance emphasizes the necessity of providing a short form that has been translated into a language understandable to the prospective subject and approved by the IRB. Additionally, the guidance dictates that the IRB must approve a written summary of what is to be said to the subject or the legally authorized representative. This underscores the importance of ensuring that study subjects are provided with the relevant information in their native language to enable a comprehensive understanding before consenting to participate in a clinical investigation.", "In the context of the given information from the E14 Clinical Evaluation of QT:QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs, the most appropriate metric to assess a drug's effect on QT/QTc interval when the data are collected in a placebo-controlled parallel design study (i.e., when there is no corresponding placebo value for each patient) would be to use the largest time-matched mean difference between the drug and the baseline value. In placebo-controlled parallel design studies, where there is no specific corresponding placebo value for each patient, utilizing the baseline value as a reference for each patient can provide a suitable comparison to assess the drug's effect on QT/QTc intervals.\n\nMoreover, the incorporation of concentration-response modeling of QTc data can serve as an alternative approach for assessing the drug's effect on QT/QTc intervals, particularly when dealing with nonclinical safety studies. Concentration-response analysis, which utilizes all available data across all doses to characterize the potential for a drug to influence QTc, provides a comprehensive assessment of the drug's impact on QT/QTc intervals and can supplement the traditional analyses.\n\nUnderstanding the concentration-response relationship can help predict the QT effects of doses, dosing regimens, routes of administration, or formulations that were not studied directly, thus providing valuable insights into the potential effects of the drug on QT/QTc intervals across a range of exposure scenarios.\n\nAdditionally, the incorporation of the thorough QT/QTc study design elements, such as the timing of ECGs, dose-effect and time course relationships, and baseline measurements, plays a crucial role in addressing intrinsic variability in the assessment of QT/QTc intervals and in characterizing the dose-response relationship for QT/QTc prolongation.\n\nIn summary, when conducting a placebo-controlled parallel design study for assessing a drug's effect on QT/QTc intervals, the use of baseline-adjusted comparisons and concentration-response modeling, along with thorough QT/QTc study design elements, can provide a comprehensive assessment of the drug's impact on cardiac repolarization and proarrhythmic potential.", "No, substances that have been considered and not placed on the 503A Bulks List through a final rule cannot be used in compounding under 503A. As per the Section 503A Bulks List Final Rule, drug products compounded using any bulk drug substances that are identified as not being included on the list do not qualify for the exemptions under 503A of the FD&C Act. This rule provides the explicit criteria for evaluating bulk drug substances for inclusion and lists specific substances that were not included due to regulatory reasons, demonstrating that they are not appropriate for use in compounding drug products under section 503A of the FD&C Act. Therefore, compounding with substances that are not on the 503A Bulks List may subject the compounder to regulatory action.", "As per the details in the \"Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans Guidance for Industry\" from the U.S. Department of Health and Human Services, when submitting an initial pediatric study plan (PSP), sponsors are advised to apply the \"Pediatric Information Incorporated Into Human Prescription Drug and Biological Product Labeling Guidance for Industry.\" This guidance recommends that sponsors should submit an initial pediatric study plan (iPSP) before the end-of-phase 2 meeting. It specifically addresses the timing of iPSP submission and the content requirements for the iPSP.\n\nThe guidance states that sponsors who are planning to submit an application for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration are required to submit an iPSP unless the drug is for an indication for which orphan designation has been granted. Additionally, a sponsor who is planning to submit an original application for a new active ingredient that is subject to the molecularly targeted cancer drug provision is also required to submit an iPSP. The iPSP should be submitted before the date on which the sponsor submits the required assessments or investigation and no later than either 60 calendar days after the date of the end-of-phase 2 meeting or such other time as agreed upon between FDA and the sponsor. It is important to note that the timing and content of the submission of an iPSP are described in detail in this guidance.\n\nTherefore, based on the regulatory context provided, the proposed biosimilar product applicant should submit an initial pediatric study plan (PSP) before the end-of-phase 2 meeting, as specified in the content guidelines for submitting initial pediatric study plans.", "In section 17.1 (Important Baseline Efficacy/Effectiveness Information) of the Periodic Benefit-Risk Evaluation Report (PBRER) as per the ICH E2C(R2) guideline, the efficacy/effectiveness information should include important baseline data related to the efficacy and effectiveness of the medicinal product. This information should be presented to provide a comprehensive, concise, and critical analysis of any new or emerging efficacy/effectiveness data during the reporting interval, in the context of cumulative information. The report should cover any pertinent new efficacy/effectiveness information that has become available, examining whether the new information obtained is consistent with the previous knowledge of the medicinal product's benefit and risk profile. The assessment of the benefit should be limited to approved use, taking into account the risks associated with all uses of the product.\n", "Based on the provided contexts, the \"Good Laboratory Practice for Nonclinical Studies\" regulation (21 CFR Part 58) is not specifically mentioned as applicable to In Vitro Diagnostic Device studies that are the focus of the given regulatory guidelines. The guidance primarily references 21 CFR 812 for nonclinical studies regarding investigational device applications, and 21 CFR parts 50 and 56 for protection of human subjects and informed consent requirements.\n\nWhile the regulations and guidelines cited in the provided contexts do not directly mandate adherence to 21 CFR Part 58 for the IVD studies in question, it's important to note that the omission of specific mention does not always imply the regulations are not applicable to certain aspects of the studies. Therefore, it is recommended to consult directly with the responsible FDA staff or regulatory authorities for definitive guidance on the application of \"Good Laboratory Practice for Nonclinical Studies\" regulations to specific IVD studies.", "In the context of the Sponsor-Investigator-IRB Interrelationship Guidance for Institutional Review Boards and Clinical Investigators and the related contexts provided, the focus should be on the requirements and responsibilities related to the conduct of clinical investigations and the roles of sponsors, investigators, and IRBs.\n\nRegarding the specific question about whether co-investigators should be listed on the FDA Form 1572 in Section #1 and whether it is acceptable to have more than one investigator at a single site, the relevant information would be as follows:\n\nAccording to the regulations described in the provided contexts, 21 CFR part 312 stipulates that a sponsor is responsible for ensuring that each investigator obtains IRB review and approval for the research they conduct. The investigator\u2019s commitment to ensure that the IRB requirements are met is obtained from each investigator under 21 CFR 312.53(c)(1)(vi)(d).\n\nIn the case of multicenter studies, the use of a centralized IRB review process is mentioned. This involves a central IRB conducting reviews on behalf of all study sites that agree to participate in the centralized review process. Agreements should be entered between the central IRB and the individual institutions participating in centralized review, as per 21 CFR 56.114.\n\nThe IRB must consider relevant local factors in their review, and it is noted that when a centralized IRB review process is used, the review should consider the ethical standards of the local community.\n\nIn the case of using a central IRB at unaffiliated sites, the central IRB should document and consider relevant local factors for the communities from which research subjects will be drawn.\n\nThese regulations and considerations suggest that while the FDA regulations do not explicitly require co-investigators to be listed on the FDA Form 1572 in Section #1, it is essential for each investigator involved in the research to ensure that there will be initial and continuing review by a qualified IRB for the research they conduct. It is acceptable to have more than one investigator at a single site, but proper arrangements and agreements should be made regarding the responsibilities of each investigator and the central or local IRBs for the initial and continuing review of the study.\n\nThis information highlights the importance of IRB review and approval for the conduct of clinical investigations, whether conducted by a single investigator or a team of investigators at a single site or across multiple sites.\n\nPlease note that this response provides a high-level summary of the regulatory requirements and responsibilities and does not constitute legal advice. It's important for stakeholders to consult the complete regulations and seek legal counsel for specific regulatory compliance.", "Referring to the given context from the regulatory guidelines and focusing on the relevance to the question of notifying CDER in an annual report when the filling speed line for a sterile product is increased, there seems to be no direct guidance on this specific scenario in the provided contexts. The guidelines mostly concentrate on postapproval changes, specifications, controls over purchasing and manufacturing activities, and aseptic processing for sterile products.\n\nIn the absence of explicit guidance in the provided contexts, it is essential to refer directly to the regulatory authority, CDER, to seek clarification on the specific reporting requirements for the described scenario. Communicating directly with the appropriate FDA staff responsible for implementing the guidance or consulting the contact numbers listed in the provided context would be the most reliable way to address this question and ensure compliance with the regulatory requirements.", "Based on the guidance provided in the documentation, the determination of the added sugars contribution from concentrated fruit or vegetable juices should be made on a weight basis. The amount of added sugars declared on the label must be in grams (21 CFR 101.9(c)(6)(iii)). Additionally, when calculating the weight of added sugars per serving, it may be necessary to consider the densities of both the finished juice product and the single-strength juice of the same type. Therefore, the added sugars contribution from concentrated fruit or vegetable juices should be quantified in grams as per the FDA's Policy on Declaring Small Amounts of Nutrients and Dietary Ingredients on Nutrition Labels."]